secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-037609
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024
--------------------------------------------------------------------------------

- Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.
- Net loss $34.4M ($7.66 per share) for FY2023; total operating expenses $38.1M including $16.2M one-time charges from reverse merger.
- CARPO Phase 2b trial of Auxora in acute pancreatitis enrollment on track; topline data expected Q2 2024.
- KOURAGE Phase 2 trial for severe AKI with AHRF cleared by FDA; first patient enrollment Q2 2024, data expected 2025.
- CRSPA Phase 1/2 trial for asparaginase-induced pancreatic toxicity expanded to Phase 2; initial cohort data showed fewer hospital days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/0000950170-24-037609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024037609/calc-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer